News

Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
pharmaphorum19h
Lilly hit as PBM drops Zepbound, but retains Wegovy
Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...
Zacks Investment Research on MSN6h
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...
pharmaphorum19h
Lilly gets second approval, in Japan, for Alzheimer's drug
Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...